PROxAbs: Next generation PROTACs to access difficult targets
In collaboration with YUMAB, scientists from Merck KGaA have developed a PROTAC-Antibody shuttle (PROxAb) to improve efficacy and therapeutic applicability of PROTACs. Read more
Automated customized antibody purification with flowbot ONE
Automating small-scale purification, e.g., of antibodies, can enable more research, shorten workflows, free up time for other tasks, and standardize results. This application note by flow robotics demonstrates the development of an automated purification solution for human IgG samples (YUMAB) using the flowbot® ONE* and PhyTip® columns. Read more
YUMAB and MOLCURE Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets
YUMAB and MOLCURE Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets YUMAB GmbH (“YUMAB”), a leading antibody discovery CRO headquartered in Braunschweig, Germany, and MOLCURE Inc. (“MOLCURE”), an AI-driven drug discovery company based in Kawasaki, Japan, announced their on-going collaboration now includes advancing the application of zero-shot AI technology for antibody discovery. […]
BioCopy and YUMAB announce partnership for development of innovative safeTY-engager® platform
Accelerating the development of highly specific antibodies against pHLA targets to fight cancer. – The development of highly specific T cell engagers directed against pHLA tumor targets will be quick and easy. – BioCopy’s innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. – […]
